Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study.

Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Theodore H. Welling,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Marie Dela Cruz,Lixin Lang,Jaclyn Neely,Ignacio Melero

Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study.

2016

Anthony B. El-Khoueiry
Bruno Sangro
Thomas Yau
Todd S. Crocenzi
Theodore H. Welling
Winnie Yeo
Akhil Chopra
Jeffrey Anderson
Christine Marie Dela Cruz
Lixin Lang
Jaclyn Neely
Ignacio Melero

4012Background: For pts with advanced HCC on sorafenib (sor), overall survival (OS) is 11 mo; median OS with best supportive care (BSC) post-sor failure is 7–8 mo.Safety and preliminary antitumor e...

Keywords:

Nivolumab
Hepatocellular carcinoma
Interim analysis
Oncology
Medicine
Checkmate
Internal medicine
antitumor activity
Sorafenib
in patient
dose escalation
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations